Related Experiment Video
Updated: Mar 3, 2026
Stimulation of Notch Signaling in Mouse Osteoclast Precursors
Published on: February 28, 2017
Targeting the STK39/ARID2 Axis to Inhibit NF-κB Signaling: A Novel Pathway for Mesenchymal Stem Cell Osteogenic
Yang Wang1, Dong Wei1, Zhineng Chen2
1Department of Traditional Chinese Orthopedics, Hangzhou Xiaoshan District Traditional Chinese Medicine Hospital, Zhejiang, China.
Objectives:
Osteoporosis (OP) is a prevalent bone disease characterized by reduced bone mass and increased fracture risk, in part due to impaired osteogenic differentiation of bone marrow-derived mesenchymal stromal cells (BMSCs). Loss of AT-rich interactive domain-containing protein 2 (ARID2) attenuates BMSC osteogenesis, but the underlying mechanism remains to be elucidated.
Methods:
Human BMSCs were induced to undergo osteogenic or adipogenic differentiation. Lentiviral transduction was used to silence ARID2 and/or overexpress serine/threonine kinase 39 (STK39). Effects on BMSC fate were assessed by quantitative reverse-transcription PCR (qRT-PCR), MTT assay, alkaline phosphatase (ALP) staining, Alizarin Red S (ARS) staining, Oil Red O staining, and western blotting.
Results:
ARID2 expression increased over time during osteogenic induction. ARID2 silencing reduced BMSC proliferation and osteogenic differentiation while favoring adipogenesis. Conversely, STK39 overexpression enhanced proliferation and osteogenic differentiation and attenuated nuclear factor κB (NF-κB) signaling during osteogenic induction; these effects were reversed by ARID2 silencing.
Conclusion:
The STK39-ARID2 axis promotes osteogenic differentiation and suppresses adipogenic differentiation of BMSCs, at least in part via inhibition of NF-κB signaling. These findings highlight a potential molecular target for therapeutic strategies in OP.
Insights
The STK39-ARID2 pathway promotes bone formation by enhancing mesenchymal stem cell differentiation and reducing fat cell formation, offering a new target for osteoporosis treatment.
Area of Science:
- Cell Biology
- Molecular Biology
- Regenerative Medicine
Background:
- Osteoporosis (OP) is a bone disease linked to reduced bone mass and increased fracture risk.
- Impaired osteogenic differentiation of bone marrow-derived mesenchymal stromal cells (BMSCs) contributes to OP.
- The precise mechanism by which AT-rich interactive domain-containing protein 2 (ARID2) influences BMSC osteogenesis is unclear.
Purpose of the Study:
- To investigate the role of ARID2 in BMSC differentiation.
- To elucidate the mechanism underlying ARID2's effect on osteogenesis and adipogenesis.
- To explore the relationship between STK39 and ARID2 in BMSC fate determination.
Main Methods:
- Human BMSCs were cultured and induced for osteogenic or adipogenic differentiation.
- Lentiviral vectors were used to silence ARID2 or overexpress STK39.
- Cell proliferation, differentiation markers (ALP, ARS, Oil Red O), and signaling pathways (NF-κB) were analyzed using qRT-PCR, MTT assays, and western blotting.
Main Results:
- ARID2 expression increased during osteogenic induction.
- ARID2 silencing inhibited BMSC proliferation and osteogenesis while promoting adipogenesis.
- STK39 overexpression boosted proliferation and osteogenesis, and suppressed NF-κB signaling, effects counteracted by ARID2 silencing.
Conclusions:
- The STK39-ARID2 axis promotes osteogenic differentiation and inhibits adipogenic differentiation of BMSCs.
- This axis appears to function partly through the suppression of NF-κB signaling.
- The STK39-ARID2 pathway represents a potential therapeutic target for osteoporosis.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
01:16TGF - β Signaling Pathway
01:19Mesenchymal Stem Cells